Tofacitinib Yields Rapid & Sustained Improvement in JIA
FDA Discussed 2021 Drug Warnings & Approvals at ACR Annual Meeting
FDA Requires New Boxed Warnings on JAK Inhibitors, Places Restrictions on Use
Janus Kinase Inhibitors Promising for Difficult-to-Treat RA
Tofacitinib Promising for COVID-19 Pneumonia
Health Canada Approves CT-P13 SC for RA; Plus Tofacitinib May Increase Cardiac & Cancer Risks
Study Examines Tofacitinib’s Long-Term Cardiovascular Risk & More
Late-Breaking Abstract Session Spans the Realm of Drug-Related Research
FDA Approves Tofacitinib for Young Patients with Active Polyarticular JIA
- 1
- 2
- 3
- …
- 6
- Next Page »